Avalyn Pharma Appoints Robert J. Meyer, MD, to Board

BOSTON, Sept. 16, 2026 /CourierPR/ -- Avalyn Pharma Inc, a clinical-stage biopharmaceutical company focused on inhaled therapies for serious, rare respiratory diseases, has appointed Robert J. Meyer, MD, to its Board of Directors. Meyer brings extensive experience in respiratory drug development and regulatory affairs, having served as a Principal of Drug and Biologics Products at Greenleaf Health, now Eliquent Life Sciences.

Dr. Meyer's appointment is seen as a significant step for Avalyn, which is currently advancing multiple inhaled therapy programs. Lyn Baranowski, CEO of Avalyn, expressed enthusiasm about Meyer's addition to the board, stating, "As an accomplished pulmonologist and regulatory leader, Bob brings a unique perspective on the regulatory, clinical, and strategic considerations that drive successful drug development. His guidance will be invaluable as we advance our AP01, AP02, and emerging combination therapy candidate AP03."

Avalyn's AP01 program is an optimized inhaled formulation of pirfenidone, currently being evaluated in MIST, a global Phase 2b clinical trial for progressive pulmonary fibrosis (PPF). AP01 has shown encouraging safety and clinical activity in Phase 1b and multi-year open-label extension trials, with long-term data supporting the potential to preserve lung function while improving tolerability compared to historical oral pirfenidone.

The company's AP02 program involves an optimized inhaled formulation of nintedanib, currently being evaluated in AURA, a global Phase 2 clinical trial for idiopathic pulmonary fibrosis (IPF). Additionally, Avalyn is advancing AP03, an inhaled fixed-dose combination of pirfenidone and nintedanib, designed to deliver multiple antifibrotic mechanisms through a single lung-targeted platform.

Dr. Meyer's background includes over 25 years of leadership experience in regulatory, academic, and industry roles. Prior to his work at Greenleaf Health, he served as Director of the Virginia Center for Translational and Regulatory Sciences at the University of Virginia School of Medicine. His tenure at the FDA spanned more than 15 years, where he held various leadership positions, including Director of the Office of Drug Evaluation II within the Center for Drug Evaluation and Research. He also served as Director of the Division of Pulmonary and Allergy Drug Products and held senior leadership roles at Merck Research Laboratories.

Dr. Meyer's appointment underscores Avalyn's commitment to transforming the treatment paradigm for pulmonary fibrosis and other serious, rare respiratory diseases. Meyer.

Avalyn aims to establish a new standard of care in pulmonary fibrosis through inhaled, lung-targeted therapies, leveraging its proprietary drug-device approach and deep expertise in rare respiratory disease development. The company's focus on optimizing inhaled formulations of established antifibrotic medicines is designed to enhance local efficacy and reduce systemic side effects, addressing the tolerability challenges that limit the use of current antifibrotic therapies.